title: Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
abstract: There is an ongoing debate whether platelet concentrates (PCs) prepared from either whole-blood donations or by plateletpheresis are superior. Usage of these two product types varies greatly between countries and individual institutions. Some use mainly apheresis PCs; others prefer pooled PCs which are produced from whole-blood donations. This review summarizes the existing information on these product types. In the first part data on quality, efficacy and safety are reviewed. It is important to note that the issue cannot be answered just by comparing 'the' apheresis platelet concentrate versus 'the' pooled platelet concentrate. Other factors which determine the quality of a product, e.g. residual leukocyte count, plasma content, additive solution or storage period may be even more important. The focus of the debate should be shifted. It is much more needed to further improve the overall quality of PCs and to optimize treatment of thrombocytopenic patients than to concentrate on a single-edged view on just the preparation method. In the second part of this review we compare the product types from the donor's point of view. If PCs which are equally safe and effective can be obtained by various methods, ethics and the safety of the healthy volunteer donor tips the scales. The decision on the use of a particular product type should take into account all aspects of efficacy, side effects and availability of the product as well as the donor's perspective and the commitment to maximize the use of the valuable whole-blood donation.
authors.affiliation: Red Cross Blood Service Baden-Württemberg-Hessen, Germany. h.schrezenmeier@blutspende.de
authors.forename: H
authors.initials: H
authors.lastname: Schrezenmeier
authors.forename: E
authors.initials: E
authors.lastname: Seifried
mesh_terms: D001782:Blood Donors / Q000941:ethics; D001792:Blood Platelets / Q000166:cytology / Q000502:physiology*; D006801:Humans; D015539:Platelet Activation; D017713:Platelet Transfusion / Q000009:adverse effects / Q000941:ethics / Q000379:methods; D010983:Plateletpheresis / Q000941:ethics / Q000379:methods*